Back to Report Store Home

Frontier Pharma: Type 2 Diabetes Mellitus – GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • Published: Dec-2016
  • Report Code: GBIHC417MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Executive Summary 5

2.1 Large and Competitive Market Landscape Driven by Rising Prevalence 5

2.2 Investment in First-in-Class Innovation Remains Strong 5

2.3 Opportunities for Investment in First-in-Class Product Development are Considerable 5

3 The Case for Innovation 6

3.1 Growing Opportunities for Biologic Products 7

3.2 Diversification of Molecular Targets 7

3.3 Innovative First-in-Class Product Development Remains Attractive 7

3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8

3.5 Sustained Innovation 8

3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 10

4.1 Disease Overview 10

4.2 Classification of Diabetes Mellitus 10

4.3 Symptoms 11

4.4 Epidemiology 11

4.5 Etiology 12

4.6 Pathophysiology 12

4.7 Co-morbidities and Complications 14

4.8 Management and Treatment of Type 2 Diabetes Mellitus 16

4.8.1 Non-insulin T2DM Therapies 17

4.9 Insulin-Based T2DM Therapies 20

4.10 Overview of Marketed Products in Type 2 Diabetes 21

4.11 Unmet Need and Commercial Opportunities in T2DM 24

5 Assessment of Pipeline Product Innovation 25

5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 25

5.2 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 29

5.3 First-in-Class Programs by Molecular Target Category 29

6 Type 2 Diabetes Mellitus Signaling Network, Disease Causation and Innovation Alignment 48

6.1 Complexity of Signaling Networks 48

6.2 Signaling Pathways and First-in-Class Molecular Target Integration 48

6.3 First-in-Class Matrix Assessment 48

7 First-in-Class Target and Pipeline Program Evaluation 54

7.1 Pipeline Programs Targeting XXX 54

7.2 Pipeline Programs Targeting XXX 56

7.3 Pipeline Programs Targeting XXX 57

7.4 Pipeline Programs Targeting XXX 58

7.5 Pipeline Programs Targeting XXX 60

7.6 Pipeline Programs Targeting XXX 61

7.7 Pipeline Programs Targeting XXX 62

7.8 Pipeline Programs Targeting XXX 64

7.9 Pipeline Programs Targeting XXX 65

7.10 Conclusion 67

8 Strategic Consolidations 68

8.1 Industry-Wide First-in-Class Deals 68

8.2 Licensing Deals 69

8.3 Co-development Deals 74

8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals 79

9 Appendix 85

9.1 References 85

9.2 Abbreviations 90

9.3 Research Methodology 91

9.4 Secondary Research 91

9.4.1 Market Analysis 91

9.4.2 Pipeline Analysis 91

9.4.3 First-in-Class Matrix Assessment 92

9.4.4 First-in-Class Target Profiles 92

9.4.5 Licensing and Co-development Deals 92

9.5 Contact Us 92

9.6 Disclaimer 92

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$6995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$13990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$20985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards